Bifrost Biosystems

Executive Summary

Bifrost Biosystems is a San Diego-based private company founded in 2021, operating at the intersection of diagnostics and AI/machine learning. Its proprietary platform connects single-cell phenotypes—including morphology, protein localization, cellular responses, and cell-cell interactions—to underlying genetic alleles at massive scale. By integrating high-throughput experimental data with advanced software, Bifrost enables researchers to rapidly transition from experiment to actionable insights, accelerating drug discovery, biomarker identification, and precision medicine applications. The platform's ability to link phenotypic traits directly to genetic variants could significantly improve the efficiency of cell-based assays and therapeutic development.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Strategic Partnership with Pharma/Biotech50% success
• Q2 2026Platform Commercial Launch or Major Update80% success